Efficacy and Safety of Sirolimus in Lymphangioleiomyomatosis

This trial showed that in patients with lymphangioleiomyomatosis (LAM), a progressive, cystic lung disease in women, sirolimus therapy was associated with stabilization of lung function, reduction in symptoms, and improvement in qualityof-life measures. Lymphangioleiomyomatosis (LAM) is an uncommon...

Full description

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 364; no. 17; pp. 1595 - 1606
Main Authors:	McCormack, Francis X, Inoue, Yoshikazu, Moss, Joel, Singer, Lianne G, Strange, Charlie, Nakata, Koh, Barker, Alan F, Chapman, Jeffrey T, Brantly, Mark L, Stocks, James M, Brown, Kevin K, Lynch, Joseph P, Goldberg, Hilary J, Young, Lisa R, Kinder, Brent W, Downey, Gregory P, Sullivan, Eugene J, Colby, Thomas V, McKay, Roy T, Cohen, Marsha M, Korbee, Leslie, Taveira-DaSilva, Angelo M, Lee, Hye-Seung, Krischer, Jeffrey P, Trapnell, Bruce C
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 28.04.2011
Subjects:	Adult Double-Blind Method Female Forced Expiratory Volume - drug effects Human subjects Humans Intention to Treat Analysis Kinases Lungs Lymphangioleiomyomatosis - drug therapy Lymphangioleiomyomatosis - physiopathology Medication Adherence Middle Aged Observation Quality of Life Sirolimus - adverse effects Sirolimus - blood Sirolimus - therapeutic use TOR Serine-Threonine Kinases - antagonists & inhibitors Vascular endothelial growth factor Vital Capacity - drug effects Womens health
ISSN:	0028-4793, 1533-4406, 1533-4406
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!